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CHAPTER I 
INTRODUCTION 
The purpose of this work was to study the metabolism of carbon-14-
l~beled glucose in C3H mice with and without the factor for mammary 
tumor (33). This method could lead to a method for identifying individ-
ual C3H mice with the factor~ Determination of the effect of drugs ori 
the metabolic rates of carbon-14-labeled glucose in C3H/HeJ mice might / 
be a useful test for screening compounds as anti-cancer agents. 
The apparatus used in this study for collection of.respiratory 
. 
carbon dioxide from an intact animal is similar to the Roth metabolic 
cage (37), a useful pharmacologic ·tool for studying ~ vivo metabolism 
rates. The apparatus has two parts: (a) a small chamber with an inflow 
of air that· is free of carbon .:dioxide and an outflow of air containing 
radioactive carbon dioxide and (b) a system for trapping and measuring 
this carbon-14 dioxideo 
The carbon..,-14-labeled glucose and citric acid used in this research 
are oxidized and excreted as respiratory carbon-14 dioxide (Figure 1). 
Citric acid is an intermediate in the tricarboxylic acid cycle (TCA)o 
Glucose can be oxidized via the hexose monophosphate pathway (HMP) and 
the Embden..,-Meyerhoff pathway (EMP) to form pyruvate, whi~h is.converted 
to lactate or to acetyl CoA. Acetyl CoA is a precursor of the TCA. 
Alteration of the metabolism by a pharmacologic agent is reflected in a 
change in the amount of carbon-14 dioxide in the expired air, 
1 
Glucose ---~Glucose-6-phosphate HMP~co2 
F<uctose-1, l:hospha tej 
1-
Dihydroxyacetone Phosphate ~ )Glyceraldehyde.;..3-phosphate 
Acetyl 
l 
co2 
CoA ~ 1-Pyruvate ~Lactate 
2 
Figure L Oxidation of Carbon-14"'-Labeled Substrates to Carbon~l4 Diox-
ide by Major Metabolic Pathways 
Thrt?e of the four anticancer drugs used in·this work have been or 
will be clinically teste.d as anticancer drugs: . depo-test0sterone 
cypionate (DTC); 2-oxo-3-ethoxybutyraldehyde bis(thiosemicarbazori.e) 
(KTS) (27), and 3-hydroxy-2-pyridinecarbaldehyde thiosemicarbazone 
(HEFTS) (8). The fourth, polyacrylic acid (PAA), has shown significant. 
activity against the intramuscular Walker sarc.oma of the rat (18). 
The trapping solution for carbon-14 dioxide is an organic quater .... 
nary ammonium base the excess of which can be titrated with a standard 
solution of hydrochloric acid to determine carbon dioxide quantitatively; 
the trapping solution can be counted in a liquid scintillation counter 
to determine radioactivity. 
CHAPTER II 
HISTORICAL 
Warburg postulate.din 1926 that.respiration is impaired and glycoly-
sis is increased.in.tumor cells (42). He assumed th.at -glycolysi;s is 
necessary to replace the enei;gy-yielding steps in the respiratory path-
way-.·· Although the detailed mechanism of cancer [metabolic] imbalance 
remains unknown, its reality is not questioned. _ In ~articular, the im~ 
balance between respiration.and glycolysis first emphasized by Warburg 
remains the foundation of biochemical investigations.in cancer. 
Dickens and Weil-Malherber founc1, th.at ·both· aer_obic and anaerobic 
glycolysis is a property of,tumprs (7). Le1>age found. that: tumor tissue 
was metabc,>lizedglucose differently.from normal tissues (23). Burk anq 
coworkers at the National Cancer Institute in.1956 and 1967 found evi-
dence for impaired respiration and increased anaerobic processes in 
. 
t~mor.tissues. Cancer cells descended.in vitro from a single normal 
cell were in vivo more malignant,. the higher the "fermentat:ion" rate 
(8). Wenner and Weinhouse (44) in 1956) also found in·vitro that cancer 
~ad both.anaerobic and aerobic glycolytic properties using carbon-14-
labeled gluc.ose. Hilf and Lerner (17) did in vitro ~etabolic studies in 
1969 with, mammary.cancer which supported these earlier-postulates. 
14 Glucose-1..,. C inJected intraperitoneally into ascites-bearing mice. 
wds found.to be converted entirely to lactate by.the tumor cells before 
any·significant amount reached the blood st:i::eam (16). Okita presented 
4 
metab.olic data (32a, 33) which indicated a decrease in TCA activity, 
Carbon-14~labele.d compounds have· been used in many recent pharma-
cological stuc;iies since carbon-14 can be counted with liquid.scintilla-
tion counters.and other common·inst;ruments. Liquid scintillation count-
ing is useful.with ~-emitting isotopes such as carbon-14 because of its 
high efficiency·and relative freedom from self-absorption. 
Tolbert (15) and Okita (33) have studied the ~vivo metabolic 
rates associated wit\l cancer by means of sophisticated instrumentation . 
for the continuous.monitoring of respiratory carbon-14 dioxide., Tolbert 
and associates (40) and Okita (24) developed similar instruments about 
the same time. Tolbert used a carbon dioxide monitor-employing infrared 
absorption, an-ion chamber to detect respired carbon-14, and a ratiO 
analyzer for determining specific activity, · Oki ta used an air-collect,ion 
system, aventilat;ion meter, a carbon dioxide infrared analyzer, and a 
4TI Geiger-MUller flow counter. 
Carbon-14 can also be collected and counted by the barium carbonate 
precipitation technique• This procedure usually has a very low counting 
efficiency and requires time for sample.preparation. The most conven-
ient method for determining carbon-14 activity is a liquid scintillation 
spectrometer (13) for which. the sample preparation is relatively easy 
and rapid. 
Passman, Radin and Cooper.(34) found that carbon dioxide could be 
dissolved in toluene containing a high molecular weight quaternary 
ammonium hydro~ide such as-the hydroxide of .hyamine (13), which is one 
of .the favorite carbon dioxide absorbers for .biological investigations. 
Frederickson and Ono·(ll) improved on Passman's procedure by direct 
trapping and scintillation counting rather·than batium.carbonate precipi-
5 
tation and subsequent combustion to carbon-14 dioxide for trapping. 
Several solutions have been used for radioactive carbon dioxide col-
lection and subsequent scintillation counting. Primene (a mixture of 
amines with a molecular weight of 191) in methanol (36), ethanolamine in 
ethylene glycol monmethyl ether (19), and a thixotropic scintillator gel 
suspending agent (30) have been used. All of these methods use toluene-
based scintillation solutions. They give higher efficiency and are less 
subject to the problems of chemiluminescence. 
A recent and helpful contri~ution to biological tracer studies was 
the development of solubilizer (14) which is a product of Nuclear of 
Chicago, consisting of a toluene-soluble quaternary ammonium base. 
Data from the study of the oxidation of carbon-14 labeled substrates 
to carbon-14 dioxide can be used in the evaluation of the major metabolic 
pathways: (1) glycolysis, referred to as the Embden-Meyerhoff pathway 
(EMP) in Figure 2; (2) the pentose shunt, referred to as the hexose 
monophosphate pathway (HMP) in Figure 3; and (3) the Krebs cycle, re-
ferred to as the tricarboxylic cycle (TCA) in Figure 4. All three of. 
these are energy-yielding processes (25). 
Labeled glucose has been extensively used for elucidating the path-
ways of catabolism (20, 38, 21). Most researchers have postulated that 
. 14 
the EMP yields equal amounts of carbon-14 dioxide from glucose-1~ C or 
14 glucose-6- C. The HMP yields one mole of carbon-14 dioxide for each· 
14 glucose-1- C metabolized by this pathway and no carbon-14 dioxide from 
14 glucose-6- C (Equation D, Figure 3). 
If triose phosphates are considered, the EMP yields a mole of triose 
phosphate from the C-1 or C-6 position (Equation E, Figure 2) and HMP 
yields triose.phosphate from glucose-6.14c (Equation E, Figure 3). Of 
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Figure 2. Embden-Meyerhoff Pathway Showing C-1 and C-6 Positions of 
Labeled Glucose Eliminated as Carbon-14 Dioxide. 
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Figure 3. Hexose Monophosphate Pathway Showing Elimination of C-1 Posi-
tion of Labeled Glupose as Carbon-14 Dioxide and C-6 Posi-
tion by Formation of g1yceraldehyde-3-Phosphate for Ulti-
mate Elimination of C o2 in TCA 
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Figure 4. Tricarboxylic Acid Pathway Showing Elimination of C-1 and 
C-5 of Labeled Citric Acid as Carbon-14 Dioxide and Also 
Following the C-1 and C-6 Positions of Labeled Glucose 
Into This Pathway 
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course, the triose phosphate formed from these two processes may go into 
the TCA (Figure 3) where carbon-14 dio~ide is given off. 
The key to these pathways is the ultimate fate of pyruvate. 
Pyruvate formed from labeled glucose in mammals has several metabolic 
fates shown in Figure 5 (26). An important feature to consider here is 
the increased formation of lactate since cancer is associated with 
anaerobic.and aerobic glycolysis (5, 7) and the deactivation of the TCA 
(2). 
Lactate is one of the rare dead ends in a mammalian metabolic path. 
Lactate can only return to the metabolic path by oxidation to pyruvic 
acid. The in vitro studies by Wenner and Weinhouse (44) showed that . 
14 14 . glucose-1- C and glucose-6- C were equally incorporated into. lactic 
acid. They calculated that from 77 to 94% of the total glucose going to 
carbon dioxide arose via the EMP and TCA. 
Since the spontaneous mammary tumor is hormone-dependent (3), one 
would expect mammary tumors.to react.favorably to hormonal therapy. Okita 
(33) showed that the in vivo metabolic rate of carbon dioxide elimination 
-·--
in tumor-bearing mice was altered by the administration of testosterone. 
Testosterone propionate has been shown to have an effect on mammary tumors 
(17) induced.by 7,12-dimethylbenzanthrene. Testosterone is used clini-
cally in the treatment of hr.eat cance.r (34) . Based on Okita' s findings, 
anticancer drugs cush as testosterone can alter the metabolism of the 
of the tumor-bearing C3H/HeJ mice to that of control animals. 
Another testosterone ester; used for treatment of inoperable breast 
cancer, .is the 17B-cyclopentylpropionate of testosterone (l/; depo-
testosterone cypionate (DTC). It is similar to other testosterone esters 
in physiologic activity. 2-0xo-3-ethoxybutyraldehyde bis(thiosemicar-
Glucose 
10 
HMP 
------~ co2 
from C-1 
Lactate 
I 
0 
EMP ) --)~H c1 ' 6-~2 ' 5-scoA~TCA 3 
Pyruvate Acetyl CoA 
I 
® 
0 0 - 1 6 ?.2 5 9'3 4 1 6 12 5 U3 4 - o C-C ' H -C ' -C ' C ' H =C ' -C ' 0 <E--- 2 2 2 2 
Phosphoenolpyruvate Oxaloacetate 
Figure 5. Fate of Pyruvate 
11 
0 
II -0 0-C-CH CH 2 2 
I 
-bazone) (KTS) (II) was found to have significant activity in leukemia 
VVV" 
CH3 H S I I fl CH -CH 0-CH-C=N-N-C-NH 3 . 2 2 
HC=N-N-C-NH 
I 11 2 H S ll 
Ll210 of mice (9). KTS was later found by French to have antitumor 
activity against sarcoma 180 in mice (10). Petering and associates (35) 
found KTS to have antitumor activity in rodent tumors. Mihich and Nichol 
reported significant physiological activity for KTS in the spontaneous 
manunary tumor system A of C3H mice (27). 
Another thiosemicarbazone found to have significant pharmacologic 
activity in several types of cancer is 3-hydroxy-2-pyridinecarbaldebyde 
thiosemicarbazone (HFPTS) (W). French and Blanz reported activity of 
<§)H S II 
---CH=NNH-C-NH 2 
N 
III against leukemia 11210, sarcoma 180, Lewis lung carcinoma and adeno-
VW'/ 
carcinoma 755 of mice (8). 
Another compound of interest to this work is polyacrylic acid (IV) 
'NVJ 
(PAA) (18) which was effective in the treatment of intramuscular Walker 
sarcoma of rats in tests conducted by the Cancer Chemotherapy National 
Service Center, It is a high molecular weight polymer now awaiting pre-
clinical testing. 
CHAPTER III 
EXPERIMENTAL 
Apparatus 
The metabolic carbon dioxide collection apparatus used in these 
experiments is shown in Sketch 1. Column A contains Drierite over solid 
sodium hydroxide pellets for the absorption of atmospheric carbon dioxide 
and moisture. Tygon tubing (B) is used for air-flow to and from the 
animal chamber (C). The chamber is a glass beaker of approximately 100 
ml with a two-hole rubber stopper for entrance of carbon-dioxide-free 
air and exit of respiratory carbon dioxide. A drying tube (D) with 
magnesium perchlorate to absorb the moisture from the expired air is 
.. 
inserted between the chamber and trapping solution (E). The two-armed 
carbon dioxide collection device (F) with a three-way stopcock allows 
continuous gas collection. Each arm is capped with a fritted dispersion 
bulb (G) to insure maximum surface contact of respiratory carbon dioxide 
with the NCS solution. The carbon dioxide collection device is connected 
to a water aspirator (L) by vacuum tubing (H) which gives an adjustable 
air-flow or approximately 60 ml/min ± 10 ml/min to the system. Three 
U-tubes containing Ascarite (J) and magnesium perchlorate (K) and (I) are 
inserted between the trapping solution and aspirator to allow a gravi-
metric determination of carbon dioxide which is not absorbed in the 
organic base, 
12 
8 
8 H 
D 
A c 
E 
Sketch 1 
METABOLIC CARBON DIOXIDE COLLECTION APPARATUS 
L 
-. WATER 
ASPIRATOR 
I-' 
w 
14 
Animals 
The mice in this research were inbred C3H/HeJ and C3HeB/FeJ strains 
purchased from Jackson Laboratories 1 Bar Harbor, Maine. The C3H/HeJ mice 
have a high susceptibility (> 95% incidence) to spontaneous mammary tumor 
(7), The C3HeB/FeJ mice which have a low incidence of mammary tumor 
were used as controls in the experiments. The mice were maintained on a 
Rockland Mouse/Rat Pellet diet and given tap water for drinking, They 
were not fasted prior to the experiments. The mice were kept in a room 
0 
at 25 , which was the temperature at which all experiments were con-
ductedo The C3H/HeJ mice and the C3HeB/FeJ mice were of two age groups.~ 
3~ months and 2 months. No difference in the in vivo rates of oxidation 
of labeled substrates could be attributed to age. The mice in both 
groups weighed from twenty to thirty grams. 
All carbon-14 labeled substances and drugs were administered by 
intraperitoneal injections (IP). 
Chemicals 
Ascarite (Arthur H. Thomas Co.) Lot #8358, 8 to 20 mesh was usedo 
Bromophenol Blue (Fisher Scientific). 
Citric-l,5-14c (Mallinckrodt-Nuclear). 
8018 mC/mmole; activity Oo5 mC, was used as 
0 
refrigeration at 2 • 
Reagent grade was usedo 
Lot #2336, specific activity 
received and stored under 
Depo-Testosterone Cypionate (Upjohn). 176-Cyclopentylpropionate of 
testosterone in cottonseed oil. The 100 mg/cc solution was diluted to 
30 ml with isotonic saline solution and stored under refrigerationo 
Dextrose (Baker). Reagent grade was used without further purifica-
tiono 
2,5-Diphenyloxazole (Pilot or Packard). Scintillation grade was 
used as receivedo 
15 
Drierite (Fisher Scientific). Reagent grade, 6-mesh, was used. 
Ethyl Alcohol (U.S. Industrial). Technical grade was used without 
further purification. 
Glucose-1-14c (Mallinckrodt-Nuclear). Lot #2534, specific activity 
8.8 mC/mmole; activity 0.3 mC, was used as received and stored under 
refrigeration. 
14 Glucose-6- C (Mallinckrodt-Nuclear). 
8.8 mC/mmole; activity 0.3 me, was used as 
refrigeration. 
Hydrochloric Acid (Fisher Scientific). 
used as received. 
Lot #1726, specific activity 
received and stored under 
Reagent grade 0.10 li was 
3-Hydroxy-2-pyridinecarbaldehyde thiosemicarbazone (HFPTS) was 
obtained from Frederic A. French, Mount Zion Hospital, Palo Alto, 
California, and was used as received. 
2-0xo-3-ethoxybutyraldehyde bis(thiosemicarbazone) (KTS) (Nutrition-
al Biochemicals Corporation). Reagent grade was used as received, 
Magnesium perchlorate (Fisher Scientific). Anhydrous reagent grade 
was used. 
Methyl orange (Fisher Scientific). Reagent grade was used. 
NCS Solubilizer (Amersham/Searle). Reagent grade 0.6 li solution in 
toluene was diluted to 0.1 li with toluene prior to use and stored under 
refrigeration. 
l,4-Bis[2-(5-phenyloxazolyl)]benzene (Arapahoe). Scintillation 
grade was used as received. 
Phenolphthalein (Fisher Scientific). Reagent grade indicator was 
used as received. 
Polyacrylic Acid (Nalco). Very high molecular weight c- 107) 
polymer was used as received. 
Polyoxyethylene sorbitan monostearate (Atlas). Tween 60 was diluted 
and used as a 20% solution in doubly distilled water. 
Sodium chloride (Fisher Scientific), Reagent grade was used as re-
ceived, 
Sodium hydroxide (W. H. Curtin). USP pellets were used as received. 
Toluene (Fisher Scientific). Reagent grade was used. It was stored 
over solid sodium and carefully decanted at time of use. 
16 
Instrumentation 
Beckman Research pH Meter. The potentiometric titrations were 
performed using this instrument. The samples were titrated at a constant 
0 temperature of 25 in a glass cup around which was a water jacket; water 
was circulated through a Hoke heating unit and a Brinkman Thermocool 
cooling unit. Stirring was accomplished by use of a Teflon-coated mag-
netic stirring bar and a magnetic stirrer. 
Tri-Carb Model 3320 Automatic Liquid Scintillation Spectrometer, 
This instrument had a 200-sample capacity and counted at a controlled 
f 900 temperature o It used a high-performance Bialkali photomultiplier 
tube, It also had a Packard Model 515 Digital Printer which recorded 
the sample number, counting time, and gross (or net) counts for each 
channel on a 2!.zi" paper strip. 
Preliminary Experiments 
The radioactivity of each compound was checked by a method similar 
to that employed by Waterbury and Jaffee (43). The 0.2-ml aliquot was 
dissolved in 10 ml of NCS solubilizer (0,1 ~). A 1-ml aliquot of this 
solution was counted by liquid scintillation to determine activity, The 
channels ratio method was used for determination of liquid scintillation 
counting efficiency (1), A standard quench set (Nuclear of Chicago) was 
used for establishing quench curves for appropriate corresponding ef~ 
ficiency (1). A standard quench set (Nuclear of Chicago) was.used for 
establishing quench curves for appropriate corresponding efficiency 
determinations, All carbon-14 samples on the Tri-Garb 3320 were in the 
86 to 90% efficiency range, 
17 
To insure that all carbon dioxide or carbon-14 dioxide was being 
absorbed by the trapping agent, three U-tubes (see Figure 6) filled with 
Ascarite and magnesium perchlorate were placed in the line leading to the 
water aspirator. Gravimetric determination showed that 99.7 percent of 
a11 expired carbon dioxide was being absorbed by the trapping solution. 
Gravimetric determination of carbon dioxide without collection in the 
organic base confirmed that out titration method using a colorimetric 
end-point was satisfactory for this work. Either method gave approxi-
mately the same yield of carbon dioxide which was dependent on the . 
activity of the mouse. 
A white solid that formed.when the organic base came in contact 
with water was dissolved when ethyl alcohol was added. As a result, the 
first end-point (phenolphthalein, red + colorless) was readily detect-
able. The second end-point (Methyl orange, yellow + red) was concealed 
as the color went from yellow + tan. Other indicators tried in the pH 
range of 3.1 to 4 •. 4 were bromophenol blue (3.0 to 4~6) and bromocresol 
green (3.8 to 5.4). Neither of these gave satisfactory end-points. With 
Vogel (41) as a reference, it was found that a 3:1 mixture of methyl 
orange to bromophenol blue as indicator solution gave a sharp (green + 
yellow) end-point. Potentiometric titrations confirmed that the two 
colorimetric endpoints were correct for the conversion of carbonate to 
bicarbonate and bicarbonate to carbonic acid. 
General Experimental Procedure 
A freshly prepared trapping solution of carbonate-free 0.1 li NCS 
solubilizer is used fot each experiment. This solution is quantitatively 
transferred with a 10-ml volumetric pipette to seven sealed collection 
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C3H/HeJ. 
C3Heb/FeJ Q 
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tubes. The seventh is used as a blank. 
The mouse is weighed prior to IP injection of the labeled substrateo 
The injection of the.mouse and placement in the chamber starts the carbon 
dioxide collection period •. The flow rate is maintained at 60 ml per 
minute by adjustment with the water aspirator. Collection periods are 
10 minutes for each solution unless otherwise noted. The three-way 
stopcock permits control of the air flow and continuous collection of 
expired carbon dioxide. After sixty minutes the carbon dioxide collection 
is stopped. The mouse is removed from t~e metabolism chamber and weighedo 
Each 10-ml solution containing trapped carbon-14 dioxide is divided 
into three solutions. A 5-ml aliquot is transferred using a volumetric 
pipette to a 50-ml Erlenmeyer flask which is capped off. It is diluted 
to 25-ml with ethyl alcohol• Two drops of phenolphthalein indicator 
are added to the solution and this is titrated with 0.1 N HCl to the 
first end point (pink+ colorless). Two drops of a methyl orange: 
bromophenol blue solution in the ratio of 3:1 are added and the titra-
tion is continued to the second end point (green+ yellow). The seventh. 
10-ml aliquot is treated accordingly to determine if a correction for 
absorbed atmospheric carbon.dioxide is required.· 
Two 1-ml aliquots are transferred with a volUmetric pipette to two 
5-dram scintillation vials. This aliquot is diluted to 20 ml with a 
scintillation cocktail composed of 0.1 grams l,4-bis[2-(5-phenyloxazolyl)] 
benzene and 4.0 grams diphenyloxazole.per liter of toluene for subsequent 
counting in a liquid scintillation spectrometer~ The blank solution in 
the seventh tube is treated accordingly for background and correction in 
the radioactivity determination. 
Calculations are then made to determine the specific radioactivity 
20 
(SA) of respiratory carbon dioxide, the cumulative percentage of carbon-
14 converted to carbon-14 dioxide, and disintegrations per minute per 
gram body weight. The ratio of total carbon-14 dioxide from glucose-6~14 
14 C and glucose-1- C was used to study the effects of anticancer drugs. 
The specific radioactivity of carbon dioxide is determined for each 
10-min collection period by the equation 
SA -
and has the units of microcuries per mole ~C/mole). 
The disintegration per minute per gram body weight is calculated 
from the disintegrations per.minute for the appropriate time period 
divided.by body weight in grams. The body weight was take~ as an average 
of the mouse weight at time zero and at 60 min. 
The cumulative percentage of carbon-14 converted to carbon-14 dioxide 
is determined by the addition of the percentage of radioactivity collected 
for each 10-min period. The results of this addition give the total per-
centage of radioactivity recovered in the form of carbon-14 dioxide. 
The G-6/G-l ratio .is determined by using the percentage radioactivity 
14 14 
recovered by injection of glucose-6- C and of glucose-1- C. 
14 These data are plotted as a function of time for citric-1,5- C 
14 14 
acid, glucose-1- C and glucose-6- C. The G-6/G-l ratio is used to 
correlate.the effect of anticancer drugs on the rates of oxidation in 
C3H/HeJ mice with those in C3HeB/FeJ control mice. 
In Vivo Oxidation of Citric-l,5~14c Acid 
14 The metabolism of citric-1,5- C acid, a key intermediate of the 
Krebs cycle (Figure 2), was studied by the procedure as outlined. The 
citric.acid was prepared for injection by dilution of 0.8 ml of labeled 
21 
citric acid (17.6 mC/mmole, activity 0.5 mC) to 25 ml with isotonic 
saline. Each mouse receiving citric-l,5-14c acid was injected with 0.2 
ml of an isotonic saline solution containing 2.0 µC of radioactivity, 
Intraperitoneal injections (IP) were administered to five C3H/HeJ mice 
and to five C3HeB/FeJ mice at time zero. Each was placed in the meta-
bolic carbon dioxide collection apparatus and carbon-14 dioxi4e was 
collected for ten-minutes periods with continuous trapping of the res-
piratory carbon dioxide up to sixty minutes, The results of this experi-
ment are plotted in Figure 6. The data for this experiment are in the 
Appendix. 
Because of the small difference in the results from the two kinds 
of mice, experiments were repeated with the labeled citric acid in the 
10-min to 30-min range. Three mice of each type were.used in this ex-
periment, The expired carbon dioxide was trapped for ten minutes and 
then for successive periods of five minutes up to thirty minutes, Two 
additional precancerous mice were subjected to IP injection and carbon-14 
was.collected for 30 minutes. The data are plotted in Figure 7. The 
data are in the Appendix. 
In Vivo Oxidation of Carbon-14-Labeled Glucose 
Glucose-1-14c (activity 0.3 mC) and glucose-6-14c (activity 0,3 mC) 
were prepared for Ip injection by the method of Minard (32). The 
labeled glucose was diluted with unlabeled glucose in 25 ml of isotonic 
14 14 
saline so that each mouse receiving glucose-1- C and glucose-6- C was 
injected with 0.2 ml of an isotonic saline solution containing 2,4 µC of 
radioactivity and 0.87 mg of D-glucose. This solution was kept frozen 
between experiments. 0 It was kept under.refrigeration at 2 when being 
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used. 
14 Glucose-1- C experiments were carried out using the general proce-
dure. Six C3HeB/FeJ mice and six C3H/HeJ mice were used for establish-
ing the oxidation rate of glucose.by continuous collection of respiratory 
14 
carbon dioxide. Glucose-6- C experiments duplicated the techniques 
14 
and procedures for glucose-1-. C. The results of these experiments are 
plotted in Figure 8 and 9 and the data used in obtaining these figures 
is given in the Appendix. 
From the results of these experiments, G-6/G-l determined from 
cumulative percent of carbon-14 converted to carbon-14 dioxide can be 
established for C3HeB/FeJ and C3H/HeJ animals (Table I) and used for 
comparison in later experiments. 
TABLE I 
OXIDATION OF GLUCOSE-6-14c AND GLUCOSE-1-14c DURING ONE BOUR 
Yield of co2 
From G-6, 
Yield of co2 
From G-1, 
% % 
C3HeB/FeJ 32.7 38.8 
C3H/HeJ 40.0 42.7 
G-6 
G-1 
0.84. 
0.94 
In Vivo Oxidation of Glucose-1-14c and Glucose-6-14c After Treatment 
With Depo-testosterone Cypionate 
The general procedure was used in this investigation on the effects 
l~ 14 
of a hormone on the oxidation of glucose-1- C and glucose-6- C to 
respiratory carbon-14 dioxide. The drug was prepared by diluting 0.5 cc 
of DTC solution to 13.3 ml with isotonic saline. The dose for each 
C3H/HeJ mouse was adjusted to 0.3 mg per gram of body weight (33). The 
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drug was kept under refrigeration at all times. IP inoculations were 
given two hours prior to injecting labeled glucose. Six C3H/HeJ mice 
14 14 (3 each for glucose-1- C and glucose-6- C) were used for experimental 
14 
work. Two additional mice were used with glucose-1- C to measure the 
rate of carbon-14 dioxide elimination. The data for these experiments 
are shown in the Appendix and results are summarized in Table II. 
C3HeB/FeJ 
C3H/HeJ 
TABLE II 
OXIDATION OF GLUCOSE-6-14c AND GLUCOSE-1-14c 
AFTER INJECTION OF DEPO-TESTOSTERONE CYPIONATE 
Yield of co2 
From C-6, 
Yield of co2 
From C-1, 
% % 
32.7 38.8 
40.0 42.7 
C3H/HeJ + DTC 28.6 36.3 
G-6 
G-1 
0.84 
0.94 
0.79 
In Vivo Oxidation of Glucose-1-14c and Glucose-6-14c After Treatment 
With 2-0xo-3ethoxybutyraldehyde Bis(thiosemicarbazone) 
KTS was prepared for injection by the method of Petering, Buskirk 
and Underwood (35). The KTS was ground with 95 percent ethanol con-
taining a drop or two of 20 percent Tween 60 solution and diluted with 
19 volumes of isotonic saline. It was stored under refrigeration at 2°. 
The dose for each mouse was adjusted to 50 mg/kg per day (27). 
The drug was given at 6:00 a.m. for three consecutive days. On the 
14 third day, glucose-1- C was administered at 8:00 a.m. to the first 
C3H/HeJ mouse, 9:15 a.m. to the second and 10:30 a.m. to the third mouse 
for subsequent carbon dioxide collect.ion.. Glucose-6-14c was administered 
eight hours later, at 4:00 p.m., 5:15 p.m., and 6:30 p.m., respectively, 
27 
and carbon dioxide was trapped in the organic base. The data from this 
experiment are in the Appendix and the values of G-6/G-l are listed in 
Table III. 
The third day was the last day for KTS injection. On the fifth 
day, the injection of glucose-1-14c and glucose-6-14c were repeated on 
the same time schedule. These data are shown in the Appendix and the 
results are summarized in Table III. 
Because of an apparatus failure, an additional C3H/HeJ mouse was 
treated with KTS. Glucose was injected on the fifth day for experi-
mental analysis. The results of this trial are included in Table III 
and in the Appendix. 
TABLE III 
OXIDATION OF GLUCOSE-6-14c AND GLUCOSE-1-14c AFTER INJECTION OF 
2-0X0-3-ETHOXYBUTYRALDEHYDE BIS(TH!OSEMICARBAZONE) 
C3HeB/FeJ 
C3H/HeJ 
C3H/HeJ + KTS (3) 
C3H/HeJ + KTS (5) 
Yield of co2 
From G-6, 
% 
32.7 
40.0 
.36. 6 
34,8 
31.4 
36,6 
26,2 
33.2 
(3) Three 'days, (5) five days 
Yield of co2 
From G-1, 
% 
38,8 
42.7 
31.8 
35.2 
34.7 
50.6 
48.2 
45.9 
G-6 
G-1 
0.84 
0.94 
Ll5 
0.99 
0.90 
o. 72 
0.54 
0, 72 
In Vivo Oxidation of Glucose-1-14c and Glucose-6-14c After Treatment 
With 3-Hydroxy-2-pyridinecarbaldehyde Thiosemicarbazone 
The drug was prepared for administration to C3H/HeJ mice by the 
method of Petering and associates (35). It was ground with 95 percent 
28 
ethanol containing a drop or two of 20 percent Tween 60 and diluted with 
19 volumes of isotonic saline. 0 It was stored under refrigeration at 2 • 
The dose for each mouse was adjusted to 71 mg/kg per day (8). 
Three C3H/HeJ mice were injected IP daily for three consecutive 
days at 6:00 a.m. with HFPTS. Glucose-1-14c was administered IP at 
8:00 a.m., 9:15 a.m., and 10:30 a.m. and the respired carbon dioxide for 
trapping was assayed. 14 Eight hours after the glucose-1- C experiment, 
14 glucose-6- C was injected and the carbon dioxide was collected. The 
rates of metabolism of these compounds are shown in the Appendix and the 
G-6/G-l ratio is shown in Table IV with respect to C3HeB/FeJ and C3H/HeJ 
animals. 
14 The same three mice were subjected to glucose-!- C and glucose-6-14 
C in vivo metabolism tests on the fifth day using an identical time 
schedule to that of the third day. The data from this experiment for 
the individual mice are shown in the Appendix and the results are shown 
in Table IV. 
TABLE IV 
OXIDATION OF GLUCOSE-6-14c AND GLUCOSE-1-14c AFTER INJECTION 
OF 3-HYDROXY-2-PYRIDINECARBALDEHYDE THIOSEMICARBAZONE 
Yield of co2 
From G-1, 
Yield of co2 
From G-6, 
% % 
C3HeB/FeJ 32.7 38.8 
C3H/HeJ 40.0 42.7 
C3H/HeJ + HFPTS (3) 29.6 29.8 
29.0 34.5 
42.0 49.6 
C3H/HeJ + HFPTS (5) 27.0 25.6 
3L6 25.2 
28.4 37.2 
(3) three days, (5) five days 
G-6 
G-1 
0.84 
0.94 
0.99 
0.84 
0.84 
LOS 
L25 
0.76 
29 
14 14 '· . In Vivo Oxidation of Glucose-1- C and Glucose-6- C After Treatment 
With Polyacrylic Acid 
Polyacrylic acid was prepared for injection by dissolving 5.0 mg 
in 20 ml isotonic saline solu~ion. The dose for each mouse was adjusted 
to 2.5 mg/kg per day (18). It was stored under refrigeration at 2°. 
Three C3H/HeJ mice were injected daily for three cons~cutive days 
at 6:00 a.m. No additional injections with PAA were made. On the third 
14 day, glucose-1- C was injected IP at 8:00 a.m., 9:15 a.m., and 10:30 
a.m. Respired carbon-14 dioxide was collected for successive 10-minute 
periods up to one.hour. 14 Eight hours later glucose-6- C was adminis-
tered. The results of these experiments are exhibited in the Appendix 
and the G-6/G-l ratio for each mouse is shown in Table V. This experi-
ment was duplicated on the fifth day. The results of these experiments 
are shown in the Appendix and Table V shows the G-6/G-l ratio for 
C3HeB/FeJ and C3H/HeJ mice. 
TABLE V 
OXIDATION OF GLUCOSE-6-14c AND GLUCOSE-1-14c AFTER 
INJECTION OF POLYACRYLIC ACID 
Yield of co2 
From G-1, 
Yield of co2 
From G...,.6, 
% % 
C3HeB/FeJ 32.7 38.8 
C3H/HeJ 40.0 42.7 
C3H/HeJ + PAA (3) 4Ll 43.6 
30.9 38.4 
37.0 38,4 
C3H/HeJ + PAA (5) 28.4 57.0 
26.5 30.2 
43,5 42.8 
(3) three days, (5) five days 
G-6 
G-1 
0.84 
0,94 
0, 94. 
0.80 
0,96 
0,49 
0,88 
L02 
CHAPTER V 
RESULTS AND DISCUSSIONS 
The results of this research, summarized in Table V, indicate a 
difference in the rates of metabolism of carbon-14-labeled glucose by 
C3H/HeJ mice with the factor for spontaneous mammary tumors and by 
C3HeB/FeJ mice without the factor. The metabolism of the C3H/HeJ mice 
can be associated with a increase in glycolysis and a decrease in the 
tricarboxylic acid cycle activity. Depa-testosterone cypionate, an 
ester of testosterone, altered the rate of· metabolism of C3H/HeJ mice 
to that of C3HeB/FeJ mice. 2-0xo-3-ethoxybutyraldehyde bis(thiosemi-
carbazone) appeared to alter the in vivo rate of metabolism of mice 
with the mammary tumor factor to that of mice without the factoro 3-
Hydroxy-2-pyridinecarbaldehyde thiosemicarbazone and polyacrylic acid. 
had smaller effects on the in vivo oxidation of labeled glucose in 
C3H/HeJ mice. 
The apparatus used in this research is an economical tool for 
metabolism studies but lacks precision. Okita (33) found a G-6/G-1 
ratio of 0,66 for C3HeB/FeJ compared to 0,84 in these experimentso He 
found the G-6/G-l ration for C3H/HeJ mice to be 1.04, comparable to the 
value of Oa94 in these experiments. Although the differences in the 
G-6/G-l ratios found by Okita are larger, the magnitudes of these ratios 
found in this work are similar to his. 
C3H/HeJ mice can be distinguished from C3HeB/FeJ mice (Table XVI) 
30 
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by use of the method and apparatus used in this research. This method 
might aid in the detection of a precancerous state prior to the appear-
ance of malignant growth. 
The decreased rate of metabolism of citric-l,s-14c acid in C3H/HeJ 
mice compared to that in C3HeB/FeJ mice indicates decreased Krebs cycle 
activity. The G-6/G-l ratio in C3H/HeJ mice compared to that in C3HeB/ 
FeJ animals (0.94 versus 0.84) indicates an increase in glycolysis. The 
formation of lactate is a dead end in metabolic pathways, Therefore, 
whet.her glucose is labeled in the C-1 or c-6 position, the rate of 
eliminatipn of carbon-14 dioxide should be about:. the .same in the C3H/HeJ 
mice with the factor. The lactate formed from glycolysis must be re-
oxidized to pyruvate and eventually eliminated via the Krebs cycle. 
Since tumor tissue can utilize both aerobic and anerobic glycolysis (7), 
one would expect a slight increase in the C-1 elimination because of the 
hexose monophosphate pathway activity (44). These results confirm these 
expectation although the data of Okita (33) do not. 
14 One.would expect a greater difference in glucose-1~ C and glucose-
6-14c in C3HeB/FeJ mice because of the normal oxidative pathways, the 
Krebs cycle and the hexose monophosphate pathway, which contribute to 
14 the metabolism of the glucose-1- C. The Krebs cycle is the major means 
14 
of glucose-6- C elimination. 
Hormonal treatment of mammary tumors (17) (31) is an accepted 
clinical procedure. Depo~testosterone cypinate altered the oxidation 
of labeled glucose in precancerous C3H/HeJ mice to that of C3HeB/FeJ 
mice. 2-0xo-3~ethoxybutyraldehyde bis(thiosemicarbazone) caused the 
metabolic elimination of carbon dioxide from precancerous C3H/HeJ mice 
to be altered toward that of the C3HeB/FeJ controls on the fifth day 
32 
TABLE VI 
OXIDATION OF GLUCOSE-1-14c AND GLUCOSE-6-14c DURING 1 HOUR 
Yield of co2 Yield of co2 G-6 
From G-6, From G-1, G-1 
% % 
C3HeB/FeJ Control 32. 7 ± 1. 9 38.8 ± 2.7 0.84 
C3H/HeJ Precancerous 40.0 ± 0.5 42.7 ± L6 0.94 
C3H/HeJ + DTC 28.6 ± 1.9 36.3 ± 2.3 0.79 
C3H/HeJ + KTS (3 Days) 36.6 31.8 1.15 
34.8 35.2 0.99 
31.4 34.7 0.90 
C3H/HeJ + KTS (5 Days) 36.6 50.6 o. 72 
26.2 48.2 0.54 
33.2 45.9 0.72 
C3~/HeJ + HFPTS (3 Days) 29.6 29.8 0.99 
29.0 34.5 0.84 
42.0 49.6 0.84 
C3H/HeJ + HFPTS (5 Days) 27.0 25.6 LOS 
31.6 25.2 L25 
28.4 37.2 0.76 
C3H/HeJ + PAA (3 Days) 41.1 43.6 0.94 
30.9 38.4 0.80 
37.0 38.4 0.96 
C3H/HeJ + PAA (5 Days) 28.4 57.0 0.49 
26.5 30.2 0.88 
43.5 42.8 1.02 
33 
although not on the third day. The 3-hydroxy-2-pyridinecarbaldehyde 
thiosemicarbazone and polyacrylic acid were less effective in altering 
metabolism of the precancerous C3H/HeJ mice. Additional experiments 
should be made with more mice in order to improve the statistical treat-
ment. In particular the C3HeB/FeJ mice should be treated with the same 
compounds to determine their response. 
The analysis of variance was performed according to Steel and Torrie 
(30) to evaluate the significance of the data from these experimentso 
The analysis of variance (AOV) for the in vivo metabolism of labeled 
glucose (Table VII) was a 2 x 2 factorial design with two levels for 
each factoro The C3H/HeJ and C3HeB/FeJ mice were the two levels for 
f acter A. The glucose samples labeled in the one position and in the 
six position were the levels for factor B. 
TABLE VII 
ANALYSIS OF VARIANCE FOR IN VIVO OXIDATION OF GLUCOSE-6-14c 
AND GLUCOSE-1-14c IN UNTREATED C4H/HeJ AND C3HeB/FeJ MICE 
Source dF SS MS F 
Treatments 3 264002 
A 1 155013 155013 2306 
B .1 94061 94.61 l4o4 
AB -1 14.28 14.28 2ol8 
Error 16 104. 95 . 6.56 
Total 19 
** Main effects are highly significant o 
Oo05 
** 4o49 
4o49 ** 
4.49 
The AOV for the effect of depo-testosterone cypinate is shown in 
34 
Table \[II. It is a one-way classification since the experiment deviated 
from the others in mode of administration of the drug. 
TABLE VIII 
ANALYSIS OF VARIANCE FOR IN VIVO OXIDATION OF GLUCOSE-6-14c 
AND GLUCOSE-1-14c IN C3H/HeJ MICE AFTER TREAT-
MENT WITH DEPO-TESTOSTERONE CYPIONATE 
Source dF SS MS F 
A 1 1778.07 1778. 07 222 
** Difference among positions is highly significant. 
0,05 
** 6,61 
The AOV for 2-oxo-3ethoxybutyraldehyde bis(thiosemicarbazone), 
3-hydroxy-2-pyridinecarbaldehyde thiosemicarbzaone, and polyacrylic 
acid were performed on results obtained in three days (Table VIII) and 
five days (Table X) • 
TABLE IX 
ANALYSIS OF VARIANCE FOR IN VIVO OXIDATION OF GLUCOSE-6-14c 
GLUCOSE-l-14c IN C3H/HeJ MICE AFTER TREATMEN.T WITH 2-
0X0-3-ETHOXYBUTYRALDEHYDE BIS(THIOSEMICARBAZONE), 
3-HYDROXY-2-PYRIDINECARBALDEHYDE THIOSEMICARBA-
ZONE, AND POLYACRYLIC ACID AT THREE DAYS 
Source dF SS MS F 
Treatments 5 103.68 
A 1 30.94 30.94 0.90 
B 2 52.19 26.10 o. 76 
AB 2 20.55 10.28 0,30 
Total 17 
No significant difference among levels of either factor. 
0,05 
4,75 
3,89 
3,89 
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TABLE X 
ANALYSIS OF VARIANC~ FOR IN YIY.Q. OXIDATION OF GLUCOSE-6-14c AND 
GLUCOSE-1-14c IN C3H/HeJ MICE AFTER TREATMENT WITH 2-0X0-3-
ETHOXYBUTYRALDEHYDE BIS(THIOSEMICARBAZONE), 3-HYDROXY-2-
PYRIDINECARBALDEHYDE THIOSEMICARBAZONE, AND POLY-
ACRYLIC ACID AT FIVE DAYS 
Source 
Treatments 
A 
B 
AB 
Error 
Total 
* 
dF 
5 
1 
2 
_2 
12 
17 
SS 
965.52 
363.60 
410.09 
191.83 
699.87 
MS 
363.60 
205.05 
95.9 
58.32 
Difference among positions is significant. 
F 
6.23 
3.52 
1.64 
0,05 
* 4. 75 
3.89 
3,89 
Aov for simple effects of these three drugs are in Table XI. 
TABLE XI 
ANALYSIS OF VARIANCE OF SIMPLE EFFECTS IN VIVO OXIDATION 
OF GLUCOSE-6-14c AND GLUCOSE-1-14c FO;-C3H/HeJ MICE 
AFTER TREATMENT WITH 2-0X0-3-ETHOXYBUTYRALDEHYDE 
BIS(THIOSEMICARBAZONE, 3-HYDROXY-2-PYRIDINE-
CARBALDEHYDE THIOSEMICARBAZONE, AND 
POLYACRYLIC ACID AT FIVE DAYS 
Treatment Comparison dF MS 
G-1 and G-6 with KTS 1 388.82 
G-1 and G-6 with HFPTS 1 0.625 
G-1 and G-6 with PAA 1 166.43 
KTS, HFPTS and PAA with G-1 2 278.61 
KTS, HFPTS and PAA with G-6 2 63.65 
F 
4.75 ** 
4,75 
4,75 ** 
3.89:** 
** 3.89 
** All simple effects are highly significant except G-1 a:i.d, G-6 with HFPTS, 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
(7) 
(8) 
(9) 
(10) 
(11) 
(12) 
(13) 
(14) 
(15) 
(16) 
(17) 
(18) 
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APPENDIX 
APPENDIX 
CUMULATIVE RECOVERY OF CARBON-14 IN RESPIRED CARBON DIOXIDE, % 
Treatment Compound Mouse Mouse Time 2 min 
Injected Type · No. . 10 20 30 40 so 60 
None Citric-1,s-14c C3HeB/FeJ F03 o.s 7.9 21. 7 26.9 36.4 37.4 
F04 1.8 7.0 17.0 25.1 33.2 38.6 
FOS LS 7.9 19.0 24.4 29.7 34.4 
F06 .8 S.4 14.1 26.7 32.0 38.3 
F07 .3 6.4 17.8 22.1 30.0 32.9 
Citric-1,s-14c 
Average 1.0 6.9 17.9 25.0 32.3 36.3 
None C3H/HeJ HOS 1.S 8.S 15.5 24.1 32.7 36.6 
H06 0.6 6.1 14.1 25.1 30.6 3S.6 
::-.. H07 1.4 8.0 19.2 29.8 35.1 37.6 :::> 
H08 1.4 4.1 11.6 19.5 27.3 3S.7 
H09 1.3 7.3 20.1 29.2 33.9 37.0 
14 Average 1.2 6.8 16.1 2S.S 31.9 36.S None Citric-1,5- C C3HeB/FeJ F09 0.7 2.4 s.o 14.1 19.9 
FlO 1.9 4.6 8.0 13.4 19.S 
Fll 3.9 9.4 16.3 21.2 26.3 
Citric-1,s-14c 
Average 2.1 5.5 9.8 16.2 21.9 
None C3H/HeJ HlO .6 1.2 6.4 12.0 14.7 
Hll .1 .1 7.0 9.9 11. 7 
H12 2.8 4.9 6.9 11. 7 18.9 * 
14 Average 1.1 2.1 6.8 11.2 lS 0 2 ±, 1. 7 None Glucose-6- C C3HeB/FeJ F19 0.9 4.8 12.1 18.7 26.6 31.3 
F20 0.1 7.6 16.S 25.0 31. 7 36.8 
F21 0.4 2.8 11.7 18.1 26.2 32.4 
F22 0.7 4.0 10.9 20.3 27,l 33.S 
F23 2.4 10.0 17.2 22.2 26.3 29.7 
F24a 2.1 9.8 19.3 30.2 38.1 45.9 
Average 0.9 5.8 13.7 20.9 27.6 32.7 ± L9 
APP~·~,{C'Orttinued) 
Treatment Compound Mouse Mouse . . . . . . . . . ·, . · · · T ilile 2 min ' · · 
Injected Type -No. 10 20 30 40 50 60 
None. 14 Glucose-6- C C3H/HeJ H19 LO 7.0 15.5 24.7 33.2 4LO 
H20 .3 2.8 10.5 22.5 30.2. 38.3 
H21 .7 2.9 11.1 21.1 30.4 37.7 
H22 L2 9.0 18.8 28.5 36.8 4L7* 
H23 1.5 11.6 21.9 30.7 37.2 41.3 
H24a .4 5.6 12.6 18.3 23.4 27.9 
14 Average 0.9 6.1 14~7 25.5 33. 6· 40. 0 ± 0. 5 None Glucose-1- C C3HeB/FeJ F13 1.0 5.2 14.1 23.3 *29.7-+ 35.9+ 
F14 1.0 7.0 14.5 24.1 32.6 41.5 
F15 .8 5.6 15.3 24.9 32.3 40.6 
Fl6 1.6 8.2 14.6 26.2 34.5 40.9 
F17 LS 6.7 15.4 22.5 28.4 35.0 
F18 1.0 5.5 I2.7 20.0 25.0 32.1 
14 Average 1.2 6.5 14.8 24.2 31.9 38.8 None Glucose-!- C C3H/HeJ Hl3 .7 5.1 14.0 22.9 31. 7 38.4 
Hl4 1.1 9.1 21.3 29.0 38.0 43.8 
H15 1.4 8.3 20.0 27.8 36.6 42.7 
H16 .9 10.5 19.1 30.5 37.1 43.6 
Hl7 1.3 7.8 18.7 28.50 37.8 44.8 
Hl8a 1.5 6.0 16.0 22.3 27.4 32.4 
1 6 14 
Average. 1.1 8.2 18.6 27.7 36.2 42.7±1.6 
DTC G ucose- - C Hl8 1.2 3.7 10.6 17.0 24.5 31.4 
Hl9 .9 3.8 8 .. 9 15.3 21.1 26.1 
H20 .8 3.4 9.2 14.9 20.9 28.3 
14 Average DTC Glucose-1- C H13 .4 4.2 10.l 18.6 . 26.1 32.6 
Hl4 1.0 5.1 15.4 22.8 32.0 37.8 
Hl5 .6 6.6 14.9 * 27.0 35.4 ~ 
Hl6 1.5 9.1 19.3 28.6 33.4 39.3 I-' 
· · APPEmJJX: · febntim;ied) 
Treatment Compound Mouse Mouse · · · · · · · · "'Timei "min 
Injected Type. No. 10 20 30 40 50. oO 
Hl7a 2:.0 - 8.5 18.9 30.6 39.5 47.8 
14 Average. KTS Glucose"'."6- C H21 .06 5.5 '14.6 21.6 29.6 36.6. 
H22 1.4 6.9 14.7 23.1 29.6 34.8 
H23 1.1 5.7 14.0 20.7 26.1 31.4 
14 Average KTS Glucose-1- .C- H21 *- - ~*--· 13.8. 20:1 25.i '31.8 
H22 0.8 4.6 11.6 20.5 28.2 35.2 
H23 1.5 7.0 15.6 23.9 29.5 34.7 
14 Average KTS Gluco.se-1- C H2l 1.6 13.2 26.4 36.4 44.0 50.6 
H22 2.4 10.6 19.9 31.2 42.5 48.2 
H23a 1.1 
H24 0.8 7.8 18.4 31.0 39.6 45.9 
14 Average KTS Glucose-6- C H21 1.5 *12.7 20.4 -~25.7~-32-:-0----30.6 
H22 1.3 6.7 11.7 17.2 22.3 26.2 
H23a 3.3 15.0 23.6 31.1 36.1 40.9 
H24 0.9 5.6 . 11.1 19.8 26.1 33.2 
14 Average HFPTS Glucose-6- C H25 . 0.6 5.4 10.5 17.8 23.9 29.6 
H26 1.1 4.8 10.8 17.4 23.6 29.0 
H27 0.6 7.6 15.1 26.2 35.3 42.0 
14 Average. HFPTS Glucose-1- C H25 . 0. T 4.8 10.9 17 .4 24.4 29.8 
H26 0.8 4.3 10.0 18.2 26.0 34.5 
H27 1.1 8.8 20.9 32.7 41.9 49.6 ~ 
Average .N 
APPENDIX (Continued} 
Treatment Compound Mouse Mouse 
Injected Type No. -10 
HFPTS 14 Glucose-6- C H25 .5 
H26 1.0 
H27 .5 
14 Average HFPTS Glucose-1- C H25 .5 
H26 .9 
H2.7 2.7 
14 Average PAA Glucose-6- C H28 Ll 
H29 L3 
H30 1.5 
14 Average PAA Glucose-1- C H28 lol 
H29 0.9 
H3_0 1.0 
14 Average PAA Glucose-6- C H28 0.6 
H29 1.0 
H30 1.0 
14 Average PAA Glucose-1""". C H28 1.9 -
H29- 4.3 
H30 1. 7 
Average 
- - - _ • Time i min ' -
20 30 40 
4.9 10.0 16.2 
7.3 14.1 22.4 
6.1 13.2 19.4 
4.7 10.1 16.3 
4.2 9.8 16.1 
13.5 22.1 29.3 
9.6 19.3 27.8 
8.8 15.0 22.2 
9.1 18.6 25.0 
10:2 20.2 32.3 
8.5 13.3 25.2 
6.0 14.1 23.l 
3.7 10.7 18.5 
7.3 11.6 17.0 
10.1 22.3 30.4 
13.8 27.4 40.3 
10.1 15.1 20.4 
9.4 16.2 27.9 
50 
21.2 
27.1 
25o0 
20o7 
2L7 
34.1 
35.5 
26.5 
31.2 
38.1 
32.3 
30.6 
24.9 
21.8 
37.8 
51.0 
25.4 
35.2 
60 
27.0 
3L6 
28.4 
25.6 
25.2 
37.2 
4Ll 
30.9 
37.0 
43.6 
38.4 
38.4 
28.4 
26.5 
43.5 
57.0 
30.2 
42.8 
.p. 
w 
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